WELCOME

We highlight here interesting new articles from Molecular Psychiatry and other sources published online ahead of print.

Readers are encouraged to post comments, to which authors may respond as they wish.

This is an edited blog: only postings approved by the editor of Molecular Psychiatry will appear here.

Additional information of relevance is posted on the right hand column.

Thursday, May 28, 2009

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

To see article click here

Original Article

Molecular Psychiatry advance online publication 26 May 2009; doi: 10.1038/mp.2009.50

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

M H Bloch1, J McGuire1, A Landeros-Weisenberger1, J F Leckman1 and C Pittenger2

  1. 1Yale Child Study Center, Yale University School of Medicine, New Haven, CT, USA
  2. 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

Correspondence: Dr MH Bloch, Child Study Center, Yale University School of Medicine, PO Box 20709, New Haven, CT 06520, USA. E-mail: Michael.bloch@yale.edu

Received 22 January 2009; Accepted 13 April 2009; Published online 26 May 2009.

Top

Abstract

We sought to determine differences in efficacy and tolerability between different doses of selective serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder (OCD) using meta-analysis. We identified 9 studies involving 2268 subjects that were randomized, double-blind placebo-controlled clinical trials that compared multiple, fixed-doses of selective serotonin reuptake inhibitors (SSRIs) to each other and to placebo in the treatment of adults with OCD. Change in Y-BOCS score, proportion of treatment responders, and dropouts (all-cause and due to side-effects) were determined for each included study. Weighted mean difference was used to examine mean change in Y-BOCS score. Pooled absolute risk difference was used to examine dichotomous outcomes. Meta-analysis was performed using a fixed effects model in RevMan 4.2.8. We found that compared with either low or medium doses, higher doses of SSRIs were associated with improved treatment efficacy, using either Y-BOCS score or proportion of treatment responders as an outcome. Dose of SSRIs was not associated with the number of all-cause dropouts. Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side-effects. These results suggests that higher doses of SSRIs are associated with greater efficacy in the treatment of OCD. This SSRI efficacy pattern stands in contrast to other psychiatric disorders like Major Depressive Disorder. This greater treatment efficacy is somewhat counterbalanced by the greater side-effect burden with higher doses of SSRIs. At present, there are insufficient data to generalize these findings to children or adolescents with OCD.

No comments:

Post a Comment